Alpa Laboratorie's Q1 2024 financials show mixed results, with positive growth in PAT but declining net sales.

Alpa Laboratorie, a microcap pharmaceutical company, has recently declared its financial results for the quarter ended March 2024. The company's stock has been given a 'Hold' call by MarketsMOJO.

According to the financials, Alpa Laboratorie has seen a flat performance in the quarter, with a score of -1 compared to 12 in the previous 3 months. However, there are some positive aspects to the company's performance. The Profit After Tax (PAT) for the nine-month period has grown by 38.64% year on year, and the company has already surpassed its sales from the previous 12 months in just nine months.

On the other hand, there are some areas of concern for Alpa Laboratorie. The net sales for the quarter have fallen by -17.4% compared to the average of the previous four quarters. This is also the lowest net sales in the last five quarters, indicating a negative sales trend in the near term. Additionally, the company's non-operating income is 59.70% of its Profit Before Tax (PBT), which suggests a reliance on non-business activities for income.

Overall, Alpa Laboratorie's financial performance for the quarter ended March 2024 has been mixed. While there are some positive aspects, there are also some areas of concern that the company needs to address in order to improve its performance in the future. Investors are advised to hold their positions in the company's stock for now, as recommended by MarketsMOJO.